INTRODUCTION
Chronic heart failure (CHF) remains a leading cause of cardiovascular morbidity and mortality worldwide. 1, 2 In fact, metabolic comorbidities such as diabetes mellitus, obesity, and insulin resistance are reported as predictors of CHF in generally population alongside with these discussed as aggravating factors for worsening of CHF. 3, 4 Dysmetabolic conditions may contribute to decreasing the global cardiac deformations frequently affecting both right and left ventricles and associated with worsening of longitudinal, radial, and circumstance strain and strain rate. 5, 6 Although global longitudinal strain is well validated as reproducible technique for the measurement of ventricular longitudinal deformation with predictive value regarding a composite of cardiac death, malignant arrhythmia, hospitalization due to CHF, urgent valve surgery Background: Biomechanical stress and infl ammatory biomarkers relate to global contractility dysfunction; however, adding these biomarkers into a risk model constructed on clinical data does not improve its prediction value in chronic heart failure (CHF). Aim: The aim of this study was to evaluate whether biomarkers predict declining of left ventricular global contractility function in diabetic patients with ischemiainduced CHF.
Patients and Methods:
The study retrospectively evolved 54 diabetic patients who had systolic or diastolic ischemia-induced CHF that was defi ned as left-ventricular ejection fraction (LVEF) ≤45% or 46-55% respectively assessed by quantitative echocardiography and other conventional criteria according to current clinical guidelines. Two-dimensional transthoracic echocardiography and tissue Doppler imaging were performed according to a conventional method. Radial, longitudinal, and circumferential strain and strain rate values were obtained by speckle-tracking Imaging analysis of both LV short axis and long axis views. Serum adiponectin, NT-pro brain natriuretic peptide (BNP), osteoprotegerin, and hs-Creactive protein (CRP) were determined at baseline by ELISA. Results: We found lower global longitudinal strain and strain rate in diabetic patients with LVEF <45% than these in diabetic patients that did not have LVEF (Р=0.001 for all cases). Multivariate logistic regression analysis showed that NTproBNP (r=0.432; P=0.001 and r=0.402; P=0.001, respectively), osteoprotegerin (r=0.422; P=0.001 and r=0.401; P=0.001, respectively), hs-CRP (r=0.408; P=0.001 and r=0.404; P=0.001, respectively) were independently inversely associated with global longitudinal strain and strain rate in CHF patients.
Conclusion:
We suggest that osteoprotegerin may be useful in improving the NT-proBNP based model as predictor of decreased global contractility function in diabetic patients with CHF.
or heart transplantation, as well as acute coronary ischemic events 7 , the innate mechanisms that directly mediate cardiac mechanical disturbance are still uncertain 8 . Moreover, whether the predictive value of left ventricular global longitudinal strain is similar for patients with declined and preserved left ventricular (LV) ejection fraction (EF) is under recognized. 9 In this context, discover and validate biomarkers for improving prediction value of global longitudinal strain is considered optimistically. 10 Currently emerging infl ammatory (high-sensitive C-reactive protein [hs-CRP], osteoprotegerin) and biomechanical stress (N-terminal brain natriuretic peptide [NT-proBNP]) biomarkers are independently associated with all-cause mortality in patients with acute, acutely decompensated and chronic heart failure. [11] [12] [13] [14] However, adding this biomarker into a risk model constructed on clinical data does not improve its prediction value, especially in diabetic population, while they relate to global contractility dysfunction. 15 The aim of this study was to evaluate whether biomarkers predict declining of left ventricular global contractility function in diabetic patients with ischemia-induced CHF.
PATIENTS AND METHODS

PATIENTS
The study retrospectively evolved 54 T2DM patients who had systolic or diastolic ischemia-induced CHF defi ned as LVEF ≤45% or 46-55%, respectively, assessed by quantitative echocardiography and other conventional criteria according to current clinical guidelines. 16 Criteria of ischemic-induced CHF were discharge from the hospital after Q-wave myocardial infarction (MI) more than 3 months prior to study entry or underwent coronary angiography / revascularization procedures between February 2010 and July 2014. All the patients gave their written informed consent for participation in the study. The following are the exclusion criteria: severe kidney and liver diseases, malignancy, brain injury within 3 months before enrollment, ischemic stroke, intracranial hemorrhage, pulmonary edema, valvular heart disease, thyrotoxicosis, acute infections, trauma, infl ammations within a previous month, pregnancy, implanted pacemaker.
T2DM was diagnosed with revised criteria provided by American Diabetes Association. 17 When one or more of the following components were found (glycated hemoglobin [HbA1c] ≥6.5%; fasting plasma glucose ≥7 mmol/L; 2-h plasma glucose ≥11.1 mmol/L during an oral glucose tolerance test; a random plasma glucose ≥11.1 mmol/L; exposure of insulin or oral antidiabetic drugs; a previous diagnosis of T2DM) T2DM was diagnosed.
Current smoking was defi ned as consumption of one cigarette daily for three months. Anthropometric measurements were made using standard procedures. Patients with T2DM were treated with life-style modifi cation, diet and orally taken antidiabetic drugs except sulfonylurea derivates and glitazones. Metformin was given in individually optimized daily doses to be achieving full or partly full control for T2DM. Therefore, insulin was not used in enrolled patients.
TRANSTHORACIS ECHOCARDIOGRAPHY
Two-dimensional transthoracic echocardiography, Tissue Doppler Imaging, and Speckle Tracking TwoDimensional Echo-Cardiography (2D-STE) were performed according to a conventional method on My Lab 50 scanner (ESAOTE, Italy) equipped with an phased probe of 2.5-5.0 МHz. Left ventricular (LV) end-diastolic (LVEDV) and LV end-systolic volumes (LVESV), and LVEF were measured by modifi ed Simpson's method. 18 Radial, longitudinal, and circumferential strain and strain rate values were obtained by SpeckleTracking Imaging analysis of both apical LV short axis and long axis views. 19 The analysis was performed off-line using the original program with Two-Dimensional Strain Rate Imaging Software (SIEMENS, Germany) according to conventional method. 20 Fig. 1 shows Two-Dimensional Strain Rate echocardiography to assess heart function.
All ECG recording were collected and reviewed by unblinded single operator. The average peak systolic (Sm), early diastolic (Em), and late diastolic (Аm) myocardial velocities were measured. Early diastolic left ventricular fi lling (E) to the Аm (Е/Аm) ratio and to the Em (Е/Em) ratio were calculated. 21 
CALCULATION OF GLOMERULAR FILTRATION RATE
Glomerular fi ltration rate (GFR) was calculated with CKD-EPI formula before enrollment of the patients in the study. 22 
MEASUREMENT OF CIRCULATING BIOMARKERS
To determine circulating biomarkers, blood samples were collected at baseline in the morning (at 7-8 a.m.) into cooled silicone test tubes wherein 2 mL of 5% Trilon B solution were added. Then they were centrifuged upon permanent cooling at 6,000 rpm for 3 minutes. Plasma was collected and refrigerated immediately to be stored at a temperature of -70 о С. Serum adiponectin, NT-proBNP, osteoprotegerin were measured by high-sensitive enzyme-linked immunosorbent assays using commercial kits (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany) according to the manufacturers' recommendations. The inter-assay coeffi cients of variation were as follows: adiponectin = 5%, NT-proBNP = 6.8%, osteoprotegerin = 8.2%. High-sensitive C-reactive protein (hs-CRP) was measured by commercially available standard kit (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany). The intra-assay and inter-assay coeffi cients of variation were <5%.
Fasting insulin level was measured by a doubleantibody sandwich immunoassay (Elecsys 1010 analyzer, F. Hoffmann-La Roche Diagnostics, Mannheim, Germany). The intra-assay and interassay coeffi cients of variation were <5%. The lower detection limit of insulin level was 1.39 pmol/L.
Insulin resistance was assessed by the homeostasis model assessment for insulin resistance (HOMA-IR) 23 using the following formula:
HOMA-IR (mmol/L × μU/mL) = fasting glucose (mmol/L) × fasting insulin (μU/mL) / 22.5
Insulin resistance was defi ned when estimated HOMA-IR value was over 2.77 mmol/L × μU/mL.
Concentrations of total cholesterol (TC) and cholesterol of high-density lipoproteins (HDL-C) were measured by enzymatic method. Concentration of cholesterol of low-density lipoproteins (LDL-C) was calculated according to the Friedewald formula (1972). 24 
STATISTICAL ANALYSIS
Statistical analysis of the results obtained was performed in SPSS system for Windows, Version 22 (SPSS Inc, Chicago, IL, USA). Normal distribution of interval data was checked. The data were presented as mean (М) and standard deviation (±SD) or 95% confi dence interval (CI); as well as median (Ме) and 25%-75% interquartile range (IQR). To compare the main parameters of patient cohorts, two-tailed Student t-test or Mann Whitney U-test were used. To compare categorical variables between groups, Chi 2 test (χ 2 ) and Fisher F exact test were used. Predictors of decreased global strain rate in patients were examined in univariable and multivariable regression analysis. Coeffi cient of variables in the model and their relevant p values, odds ratios (OR) and their CI 95% were calculated for all predictors. A two-tailed probability value of <0.05 was considered as signifi cant.
RESULTS
GENERAL CHARACTERISTIC OF PARTICIPANTS
General characteristic of patients participating in the study is presented in Table 1 . The mean age for patients with T2DM was 48.50 years. Sixty three percent of the subjects were male. The median of body mass index (BMI) and waist circumference were referred 28.5 kg/m 2 and 89 cm. Cardiovascular risk factors, i.e. hypertension, dyslipidemia, smoking, were found in 66.7%, 61.1%, and 27.7% patients, respectively. The most subjects were experienced III (61.1%) and IV (29.6%) class NYHA of CHF. Circulating biomarkers of infl ammatory activity (hs-CRP), biomechanical stress (NT-proBNP, osteoprotegerin), dysmetabolic changes (adiponectin) Figure 1 . Two-Dimensional Strain Rate echocardiography. The results of speckle-tracking imaging analysis for CHF patients with LVEF ≤45% (Fig. 1A) and LVEF = 46-55% (Fig. 1B) . Table 1 . General characteristic of patients participating in the study Note: Data are presented as mean and ±SE or 95% CI; median and 25-75% IQR. Categorical variables are expressed as numerous (n) and percentages (%). P is a comparison of mean or median variables between both subject cohorts (ANOVA test). Abbreviations: CI -confi dence interval; IQR -inter quartile range; BMI -body mass index, T2DM -type 2 diabetes mellitus, TG -triglycerides, BP -blood pressure, GFR -glomerular fi ltration rate, HbA1c -glycated hemoglobin, NT-proBNP -N-terminal pro brain natriuretic peptide; HDL-C -high-density lipoprotein cholesterol, LDL-C -Low-density lipoprotein cholesterol, hs-CRP -high sensitive C reactive protein. Table 3 .
Concomitant treatment of CHF patients
Notes: ACE -angiotensin-converting enzyme, ARBs -angiotensin-2 receptor blockers. Categorical variables are presented as numerous (n) and frequency (%). were elevated slightly-to-moderately. There were no signifi cant differences between T2DM subjects with LVEF ≤45% and 46-55% regarding demographic, BMI, waist circumference, lipid abnormalities, blood pressure, heart rate, fasting blood glucose, and creatinine. However, hypertension, adherence to smoking, II and III NYHA class were found frequently in T2DM patients with LVEF=46-55% when compared with those who had LVEF ≤45%. Subjects with LVEF ≤45% demonstrated higher HOMA-IR, insulin, hs-CRP, NT-proBNP, osteoprotegerin, and adiponectin levels when compared with patients with LVEF=46-55%.
RESULTS OF ECHOCARDIOGRAPHIC EXAMINATION
The basic echocardiographic performances in CHF patients are presented in Table 2 . We found lower longitudinal global strain and strain rate in T2DM patients with LVEF ≤45% when compared with those who had LVEF=46-55% (Р=0.001 for all cases).
TREATMENT SCHEME AMONG ENROLLED PATIENTS The concomitant treatment of CHF patients is presented in Table 3 . All patients were treated with ACE inhibitors and angiotensin-II receptor blockers. There were no signifi cant differences between both cohort patients in mineralocorticoid antagonist, beta-blocker, ivabradine, loop diuretic, and statin use. Aspirin was given frequently in subjects with LVEF=46-55% (P=0.042), in opposite, other antiplatelets were added frequently to the concomitant drugs in subjects with LVEF ≤45% (P=0.046).
UNIVARIATE AND MULTIVARIATE LOGISTIC REGRESSION ANALYSIS
Using univariate logistic regression we found that global longitudinal strain and strain rate were closely associated with NT-proBNP (r=0. Multivariate logistic regression analysis showed that NT-proBNP (r=0.432; P=0.001 and r=0.402; P=0.001, respectively), osteoprotegerin (r=0.422; P=0.001 and r=0.401; P=0.001 respectively), hs-CRP (r=0.408; P=0.001 and r=0.404; P=0.001, respectively) were independently inversely associated with LV global longitudinal strain and strain rate in CHF patients.
Moreover, LV global longitudinal strain independently predicted a circulating levels of osteoprotegerin (OR=1.12; 95% CI=1.06 -1.19; P=0.001) and NT-proBNP (OR=1.10; 95% CI=1.04 -1.17; P=0.001) ( Table 4 ). The same variables were determined as predictors for declining LV global longitudinal strain rate. In multivariate models osteoprotegerin added to NT-proBNP better predicted myocardial contractility function (OR=1.18; 95% CI=1.11 -1.23; P=0.001) than osteoprotegerin (OR=1.12; 95% CI=1.06 -1.19; P=0.001) alone and NT-proBNP alone (OR=1.10; 95% CI=1.04 -1.17; P=0.001).
DISCUSSION
The results of our study show that osteoprotegerin added to NT-proBNP predicts declining of global contractility function in T2DM patients with CHF. Surprisingly, hs-CRP, adiponectin, LVEF measured by echocardiography using the Simpson biplane model, and clinical criteria (NYHA class) were not defi ned as powerful independent tools for determination of worsening of global contractility function. Although global longitudinal strain is an excellent predictor of adverse LV remodeling and cardiac events in acute heart failure and decompensated CHF with preserved LVEF, T2DM patients with CHF are not considered optimal candidates for global longitudinal strain and strain rate measurements. 25 In fact, diabetic subjects even without overall obesity and lower LVEF may have signifi cantly declining global longitudinal strain and strain rate. Therefore, a reasonable correlation between LVEF and global longitudinal strain was found in CHF subjects with declined LVEF ≤40%. 26 CHF with preserved LVEF is frequently reported among T2DM patients. Although myocardial function assessment remains a challenging part of the echocardiographic examination, however, accuracy of the results closely depend on operator experience. Therefore, reproducibility of speckle tracking echocardiography remains a matter of controversy. 27 Taken together, these facts appear to be argument for discovering a novel biological markers for risk stratifi cation of the patients with CHF, which may increase utility of speckle tracking echocardiography.
Osteoprotegerin, hs-CRP, and NT-proBNP are defi ned as emerging biomarkers related to infl ammatory activity and biomechanical stress that are associated with all-cause and cardiovascular mortality in CHF population. 11, 12 Kalaycıoğlu et al. 12 reported that osteoprotegerin was found to be an independent predictor of impaired global longitudinal strain in hypertensive T2DM patients with subclinical left ventricular dysfunction. We have shown that osteoprotegerin added to NT-proBNP is able to predict worsening of global longitudinal strain and strain rate in both cohorts of T2DM patients with moderate-to-severe CHF including reduced LVEF and preserved LVEF. Recently osteoprotegerin was defi ned potentially as biomarker for cardiovascular risk in the metabolic syndrome and adipose tissue was identifi ed as a potential source of osteoprotegerin synthesis. 28 The results of our study confi rm that osteoprotegerin added to NT-proBNP may improve prediction of declining of global contractility function in CHF patients with T2DM. Overall, a combination of both biomarkers included NT-proBNP and osteoprotegerin appears to be superior when compared with other models regarding lower LV global contractility function. Probably, biochemical stress that limits capacity of myocardial wall to deformation may be discussed as causal factor contributed in strain and strain rate. Indeed, osteoprotegerin is a member of tumor necrosis factor superfamily 29 and it is expressed in vivo osteoblasts, endothelial cells, smooth muscle cells and cardiomyocytes 30 . Osteoprotegerin is a specifi c receptor for the ligand receptor activation of nuclear transcription factor kappa beta and TNF-alpha-dependent ligand inducing apoptosis. 31 Osteoprotegerin is often seen as an indicator of infl ammatory activation in opposite of NT-proBNP, which is reported as a powerful marker of biomechanical stress. 32 Although causality factors that mediate secretion of both biomarkers are different, osteoprotegerin and NT-proBNP are able to emerge as result in stretch and tenderness of myocardial wall. Recent clinical studies have discussed such reaction in context of volume overload, worsening of CHF and acute heart failure presentation. 33, 34 We report here that both biomarkers may be useful for prediction of decreased LV global contractility in T2DM patients with moderate-to-severe CHF, but adiponectin has not demonstrated similar ability. It is an unexpected result because of a close association of plasma osteoprotegerin and adiponectin was found in diabetic patient population. 35 Therefore, it is well known that hs-CRP and adipocytokines are not able to improve integrative prediction for survival and admission rate in CHF patients. 15 Thus, unexpectedly, osteoprotegerin and NT-proBNP were found as independent predictors of worsening of myocardial function in diabetic patients with CHF, while recent clinical studies were not categorical regarding these biomarkers.
STUDY LIMITATIONS
This study has some limitations. The fi rst limitation is the small sample size that may limit the signifi cance of the present study and may increase the risk for a Type I error. The authors believe that a greater cohort of patients with more incidences detected is desirable to improve the credibility of the study. The second limitation is method of IR determination. We used the HOMA-IR equation for IR determination, while the euglycemic-hyperinsulinemic clamp technique is recommended optionally. It is needed to note that all CHF patients enrolled in the study were treated adequately and presented with stable clinical status. Antidiabetic drugs were given in several dose ranges that were adjusted individually and fi xed by physician as optimal for patient. Probably, hypervolemic patients might be reported other results and we emphasize that state is the next study limitation. Moreover, this fact should be taken into consideration before extrapolation of our results on other patient populations including those who had LVEF >55%, non-ischemic CHF and probably dysmetabolic states. We did not divide T2DM patients with CHF regarding normal weight, overweight, and obesity because of small size was presented. Overall, this is a study limitation that was not able to check interplay between body mass and circulating level of biological markers in patients with strain and strain rate declining. However, the authors suggest that these restrictions might have no signifi cant impact on the study data interpretation. To better understanding the role of infl ammatory biomarkers in prediction of declining of LV global contractility function more investigations with increased sample size and prospective design are required.
CONCLUSION
We suggest that osteoprotegerin may be useful for making improvement of the NT-proBNP based model as predictor of decreased global contractility function in diabetic patients with CHF.
